OBJECTIVE: To internally validate the renal pelvic score (RPS) in an expanded cohort of patients undergoing partial nephrectomy (PN).
MATERIALS AND METHODS: Our prospective institutional renal cell carcinoma database was used to identify all patients undergoing PN for localized renal cell carcinoma from 2007 to 2013. Patients were classified by RPS as having an intraparenchymal or extraparenchymal renal pelvis. Multivariate logistic regression models were used to examine the relationship between RPS and urine leak.
RESULTS: Eight hundred thirty-one patients (median age, 60 ± 11.6 years; 65.1% male) undergoing PN (57.3% robotic) for low (28.9%), intermediate (56.5%), and high complexity (14.5%) localized renal tumors (median size, 3.0 ± 2.3 cm; median nephrometry score, 7.0 ± 2.6) were included. Fifty-four patients (6.5%) developed a clinically significant or radiographically identified urine leak. Seventy-two of 831 renal pelvises (8.7%) were classified as intraparenchymal. Intrarenal pelvic anatomy was associated with a markedly increased risk of urine leak (43.1% vs 3.0%; P < .001), major urine leak requiring intervention (23.6% vs 1.7%; P < .001), and minor urine leak (19.4% vs 1.2%; P < .001) compared with that in patients with an extrarenal pelvis. After multivariate adjustment, RPS (intraparenchymal renal pelvis; odds ratio [OR], 24.8; confidence interval [CI], 11.5-53.4; P < .001) was the most predictive of urine leak as was tumor endophyticity ("E" score of 3 (OR, 4.5; CI, 1.3-15.5; P = .018)), and intraoperative collecting system entry (OR, 6.1; CI, 2.5-14.9; P < .001).
CONCLUSION: Renal pelvic anatomy as measured by the RPS best predicts urine leak after open and robotic partial nephrectomy. Although external validation of the RPS is required, preoperative identification of patients at increased risk for urine leak should be considered in perioperative management and counseling algorithms.
Written by:
Tomaszewski JJ, Smaldone MC, Cung B, Li T, Mehrazin R, Kutikov A, Canter DJ, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Are you the author?
Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA.
Reference: Urology. 2014 Aug;84(2):351-7.
doi: 10.1016/j.urology.2014.05.001
PubMed Abstract
PMID: 24975712
UroToday.com Renal Cancer Section
